MYC and Burkitt lymphoma: While a common feature of these translocations was the placement of MYC under the control of an unrelated distal enhancer, further investigation revealed that 70–80% of BL patients possess a t(8;14)(q24;q32) translocation rendering MYC under the control of the immunoglobulin (Ig) heavy chain enhancer, whereas 10–15% of patients acquire a t(2;8)(p12;q24) or t(8;22)(q24;q11) karyotype, related to translocation to the κ and λ light chain enhancers, respectively [97,99].